ADRB1 and breast cancer: Interestingly, Melhem-Bertrand et al. reported a beneficial effect of the β1-AR-targeting drugs metoprolol and atenolol on the recurrence of triple-negative breast cancer (TNBC) but not on ER-positive breast cancer, highlighting the importance of breast cancer receptor status on the response to beta-blockers106.